HACKENSACK, N.J., March 4, 2014
HACKENSACK, N.J., March 4, 2014 /PRNewswire/-- Champions Oncology, Inc. (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced the appointment of Ido Ben-Zvi, Ph.D., as Director of Bioinformatics and Machine Learning to exploit the company's wealth of oncology data from its TumorBank to support its Translational Oncology Solutions offerings for pharmaceutical companies.
"Our Champions TumorGrafts™ have demonstrated the ability to improve oncology drug development and the selection of treatments for patients, and in the process generate large amounts of very valuable data," said Ronnie Morris, M.D., President of Champions Oncology. "With his experience creating systems and algorithms that analyze and package data, Ido will help lead our efforts to optimize our growing TumorBank and mine the molecular and patient response data to find biomarkers to accelerate pharmaceutical drug development."
Added Dr. Ben-Zvi, "Through my due diligence into Champions Oncology, I have seen how the technology is able to help both researchers and patients. This is a terrific opportunity to create systems that will analyze the data culled from patient TumorGrafts, validation studies and research collaborations to enable pharmaceutical partners to predict the clinical effectiveness of their oncology drug candidates."
Prior to joining Champions Oncology, Dr. Ben-Zvi was a visiting researcher with Microsoft Research. In this capacity, he led development of a system to analyze large amounts of data related to the search engine Bing. Before this, he held multiple positions with Frontline PCB Solutions in software engineering, algorithm development and data mining. Earlier in his career, he held positions in software and algorithm development at Celltrex, Zapper and Technomatix.
Dr. Ben-Zvi received his doctorate in computer science from Technion-Israel Institute of Technology, his master's degree in cognitive sciences from Tel Aviv University and his bachelor's degree from The Hebrew University of Jerusalem.
About Champions Oncology
Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The company's TumorGraft technology platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments, or TumorGrafts, in a manner that preserves the biological characteristics of the original human tumor in order to determine the efficacy of a treatment regimen. The company uses this technology in conjunction with related services to offer solutions for two customer groups: Personalized Oncology Solutions, in which results help guide the development of personalized treatment plans, and Translational Oncology Solutions, in which pharmaceutical and biotechnology companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs. TumorGrafts are procured through agreements with a number of institutions in the United States and overseas as well as through the company's Personalized Oncology Solutions business. For more information, please visit www.championsoncology.com.
SOURCE Champions Oncology, Inc.